A three-molecule score based on Notch pathway predicts poor prognosis in non-metastasis clear cell renal cell carcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE
    • Publication Information:
      Original Publication: Albany, N.Y. : Impact Journals
    • Subject Terms:
      Carcinoma, Renal Cell/*metabolism ; Jagged-1 Protein/*metabolism ; Kidney Neoplasms/*metabolism ; Receptor, Notch1/*metabolism ; Transcription Factor HES-1/*metabolism; Carcinoma, Renal Cell/diagnosis ; Carcinoma, Renal Cell/surgery ; Female ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Kidney Neoplasms/diagnosis ; Kidney Neoplasms/surgery ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Recurrence, Local ; Nephrectomy ; Outcome Assessment, Health Care/methods ; Outcome Assessment, Health Care/statistics & numerical data ; Prognosis ; Proportional Hazards Models ; Signal Transduction
    • Abstract:
      We constructed a three-molecule score based on the expression of Notch pathway molecules: Jagged1, intracellular Notch1 (ICN1) and Hes1 (JIH score). To assess prognostic value of the JIH score in non-metastasis clear cell renal cell carcinoma (ccRCC), we identified 467 patients who underwent nephrectomy during 2008-2009 as our study population. Immunohistochemistry was used to evaluate the expression of these three molecules. Cox regression models were applied to construct the JIH score, while Kaplan-Meier methods, multivariate analyses and nomogram were used to explore prognostic value of the JIH score. Our result confirmed that JIH score was an independent prognosticator for both overall survival (OS) and recurrence-free survival (RFS). Survival analyses showed that a higher JIH score indicated worse clinical outcomes (JIH score 3: 58.3% and 58.0% for 6-year OS and RFS, respectively; JIH score 0: 96.7% and 91.6% for 6-year OS and RFS, respectively). Nomograms based on JIH score and other conventional clinicopathological features had a better capability in predicting patients with pT1 stage disease for both OS and RFS (84.6% and 83.9%, respectively). The JIH score is a novel prognosticator representing activation of Notch pathway for non-metastasis ccRCC, and raises an alternative strategy for excavating potential biomarkers for signal pathways.
    • References:
      Oncol Lett. 2014 Dec;8(6):2627-2633. (PMID: 25364440)
      Cancer Sci. 2012 Jul;103(7):1253-8. (PMID: 22463491)
      Urology. 2015 Feb;85(2):483.e9-483.e14. (PMID: 25559729)
      Eur Urol. 2015 May;67(5):913-24. (PMID: 25616710)
      Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5012-7. (PMID: 20194747)
      Clin Cancer Res. 2015 Mar 1;21(5):955-61. (PMID: 25388163)
      Genes Dev. 2002 Sep 1;16(17):2252-63. (PMID: 12208848)
      Cancer. 2015 Jan 1;121(1):43-50. (PMID: 25186283)
      Cancer Cell. 2014 Mar 17;25(3):318-34. (PMID: 24651013)
      Jpn J Clin Oncol. 2011 Mar;41(3):411-6. (PMID: 21062756)
      Cancer Sci. 2015 Sep;106(9):1224-31. (PMID: 26179886)
      Cancer Res. 2007 Jun 15;67(12 ):5611-6. (PMID: 17575125)
      Eur Urol. 2009 Apr;55(4):851-63. (PMID: 19155123)
      Eur Urol. 2011 Oct;60(4):644-61. (PMID: 21741163)
      Front Oncol. 2014 Sep 25;4:254. (PMID: 25309874)
      Dev Cell. 2005 Nov;9(5):617-28. (PMID: 16256737)
      Int Urol Nephrol. 2012 Aug;44(4):997-1004. (PMID: 22456765)
      Lancet. 2009 Mar 28;373(9669):1119-32. (PMID: 19269025)
      J Urol. 2005 Aug;174(2):466-72; discussion 472; quiz 801. (PMID: 16006866)
      Nat Rev Cancer. 2011 May;11(5):338-51. (PMID: 21508972)
      J Clin Invest. 2008 Jan;118(1):217-28. (PMID: 18079963)
      Cancer Res. 2001 Apr 1;61(7):3200-5. (PMID: 11306509)
      Neoplasma. 2009;56(6):533-41. (PMID: 19728763)
      Science. 1999 Apr 30;284(5415):770-6. (PMID: 10221902)
      Nature. 2006 Dec 21;444(7122):1032-7. (PMID: 17183313)
      Eur Urol. 2006 Apr;49(4):633-43. (PMID: 16481093)
      Nat Rev Urol. 2011 May;8(5):255-65. (PMID: 21487387)
      Lancet Oncol. 2015 Jun;16(6):676-85. (PMID: 25979595)
      CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. (PMID: 26808342)
      Cancer. 2009 May 15;115(10):2092-103. (PMID: 19296514)
      Nature. 2010 Apr 15;464(7291):1052-7. (PMID: 20393564)
      Cancer Res. 2004 Nov 1;64(21):7787-93. (PMID: 15520184)
      PLoS One. 2011;6(8):e23057. (PMID: 21826227)
      CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. (PMID: 25559415)
      PLoS One. 2012;7(4):e35022. (PMID: 22506064)
      Blood. 2006 Mar 15;107(6):2223-33. (PMID: 16291593)
      Pathology. 2009;41(4):335-41. (PMID: 19404845)
      J Urol. 2002 Dec;168(6):2395-400. (PMID: 12441925)
      J Clin Oncol. 2005 Dec 20;23(36):9067-72. (PMID: 16172462)
      Cancer. 2009 May 15;115(10):2028-30. (PMID: 19288573)
      J Cell Biochem. 2009 Aug 1;107(5):992-1001. (PMID: 19479935)
      Cancer. 2003 Apr 1;97(7):1663-71. (PMID: 12655523)
      Clin Cancer Res. 2009 Apr 1;15(7):2291-301. (PMID: 19258443)
      J Clin Oncol. 2004 Dec 15;22(24):4991-5004. (PMID: 15611513)
    • Contributed Indexing:
      Keywords: Hes1; Jagged1; Notch1; clear cell renal cell carcinoma; prognostic factor
    • Accession Number:
      0 (Jagged-1 Protein)
      0 (Receptor, Notch1)
      0 (Transcription Factor HES-1)
      149348-15-2 (HES1 protein, human)
    • Publication Date:
      Date Created: 20160911 Date Completed: 20180212 Latest Revision: 20191210
    • Publication Date:
      20231215
    • Accession Number:
      PMC5356573
    • Accession Number:
      10.18632/oncotarget.11849
    • Accession Number:
      27612417